1. Davies K, Barth M, Armenian S, et al. 2020; Pediatric aggressive mature B-cell lymphomas, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 18:1105–23. DOI:
10.6004/jnccn.2020.0036. PMID:
32755986.
Article
3. Gerrard M, Cairo MS, Weston C, et al. 2008; Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 141:840–7. DOI:
10.1111/j.1365-2141.2008.07144.x. PMID:
18371107.
Article
5. Patte C, Auperin A, Michon J, et al. 2001; The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 97:3370–9. DOI:
10.1182/blood.V97.11.3370. PMID:
11369626.
6. Patte C, Auperin A, Gerrard M, et al. 2007; Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 109:2773–80. DOI:
10.1182/blood-2006-07-036673. PMID:
17132719. PMCID:
PMC1852229.
Article
7. El-Mallawany NK, Cairo MS. 2015; Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 13:113–23. PMID:
25774481.
9. Moleti ML, Testi AM, Foà R. 2020; Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 189:826–43. DOI:
10.1111/bjh.16461. PMID:
32141616.
Article
11. Murphy SB. 1980; Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 7:332–9.
12. Cairo MS, Gerrard M, Sposto R, et al. 2007; Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 109:2736–43. DOI:
10.1182/blood-2006-07-036665. PMID:
17138821. PMCID:
PMC1852225.
Article
13. Anderson JR, Jenkin RD, Wilson JF, et al. 1993; Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 11:1024–32. DOI:
10.1200/JCO.1993.11.6.1024. PMID:
8501488.
Article
14. Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. 1997; Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med. 337:1259–66. DOI:
10.1056/NEJM199710303371802. PMID:
9345074.
Article
15. Hutchison RE, Laver JH, Chang M, et al. 2008; Non-anaplastic peripheral T-cell lymphoma in childhood and adolescence: a Children's Oncology Group study. Pediatr Blood Cancer. 51:29–33. DOI:
10.1002/pbc.21543. PMID:
18300314. PMCID:
PMC4447625.
Article
16. Laver JH, Kraveka JM, Hutchison RE, et al. 2005; Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 23:541–7. DOI:
10.1200/JCO.2005.11.075. PMID:
15659500.
Article
18. Burnett AK, Hills RK, Milligan DW, et al. 2010; Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 28:586–95. DOI:
10.1200/JCO.2009.22.9088. PMID:
20038732.
Article
19. Goldman S, Smith L, Galardy P, et al. 2014; Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group report. Br J Haematol. 167:394–401. DOI:
10.1111/bjh.13040. PMID:
25066629. PMCID:
PMC4198418.
Article
20. Song JS, Youn HS, Im HJ, Ghim T, Moon HN, Seo JJ. 2006; Treatment outcome and prognostic factors for children with advanced non-Hodgkin's lymphoma at a single institution. Korean J Hematol. 41:157–66. DOI:
10.5045/kjh.2006.41.3.157.
Article
21. Harker-Murray PD, Pommert L, Barth MJ. 2020; Novel therapies potentially available for pediatric B-cell non-Hodgkin lymphoma. J Natl Compr Canc Netw. 18:1125–34. DOI:
10.6004/jnccn.2020.7608. PMID:
32755987.
Article
22. Lee HG, Choi Y, Kim SY, et al. 2014; R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. Blood Res. 49:107–14. DOI:
10.5045/br.2014.49.2.107. PMID:
25025012. PMCID:
PMC4090331.
Article
23. Goldman S, Smith L, Anderson JR, et al. 2013; Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 27:1174–7. DOI:
10.1038/leu.2012.255. PMID:
22940833. PMCID:
PMC4539148.
Article
24. Li S, Seegmiller AC, Lin P, et al. 2015; B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Mod Pathol. 28:208–17. DOI:
10.1038/modpathol.2014.95. PMID:
25103070.
Article
25. Uemura S, Hasegawa D, Yokoi T, et al. 2017; Refractory double-hit lymphoma/leukemia in childhood mimicking B-precursor acute lymphoblastic leukemia at initial presentation. Rinsho Ketsueki. 58:143–9. DOI:
10.11406/rinketsu.58.143. PMID:
28321092.
26. Thirunavukkarasu B, Samanta J, Bhatia P, Bal A. 2021; De novo double-hit B-cell precursor leukemia/lymphoma - an unusual presentation as peritoneal lymphomatosis. Autops Case Rep. 11:e2021278. DOI:
10.4322/acr.2021.278. PMID:
34307232. PMCID:
PMC8214895.
Article
27. Frazer JK, Li KJ, Galardy PJ, et al. 2019; Excellent outcomes in children and adolescents with CNS
+Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol. 185:374–7. DOI:
10.1111/bjh.15520. PMID:
30117142. PMCID:
PMC6588172.
Article
28. Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. 2003; Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 82:160–5. DOI:
10.1007/s00277-003-0608-2. PMID:
12634948.
Article
29. Turcotte LM, Liu Q, Yasui Y, et al. 2019; Chemotherapy and risk of subsequent malignant neoplasms in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 37:3310–9. DOI:
10.1200/JCO.19.00129. PMID:
31622130. PMCID:
PMC7001784.
Article
30. Ehrhardt MJ, Chen Y, Sandlund JT, et al. 2019; Late health outcomes after contemporary Lymphome Malin de Burkitt therapy for mature B-cell non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 37:2556–70. DOI:
10.1200/JCO.19.00525. PMID:
31283408. PMCID:
PMC7001792.
Article